Announcements Trials
Browse Landscape

Phase

Phase 3 8Phase 2 6Phase 1/2 5Phase 1 5

Status

Active not recruiting 3Recruiting 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Carcinoma, Renal Cell 4Parkinson Disease 4, Autosomal Dominant Lewy Body 2Metastatic Castration-Resistant Prostate Cancer 1Kidney Neoplasms 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × belzutifan × Clear all
NCT07049926 2026-05-26

MK-3475-03C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
140 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT04626479 2026-05-18

MK-3475-03A

Merck Sharp & Dohme LLC

Phase 1/2 Active not recruiting
400 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04626518 2026-05-06

KEYMAKER-U03

Merck Sharp & Dohme LLC

Phase 1/2 Active not recruiting
370 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT02861573 2026-02-17

KEYNOTE-365

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
1,200 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT05468697 2026-01-23

MK-6482-024

Merck Sharp & Dohme LLC

Phase 1/2 Active not recruiting
60 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡